aTyr Pharma, Inc. (ATYR)
0.5035
+0.01
(+2.13%)
USD |
NASDAQ |
Sep 03, 16:00
0.5001
0.00 (0.00%)
Pre-Market: 08:27
aTyr Pharma Shareholders Equity (Quarterly) : 48.79M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.79M |
| March 31, 2026 | 57.93M |
| December 31, 2025 | 67.48M |
| September 30, 2025 | 80.24M |
| June 30, 2025 | 74.84M |
| March 31, 2025 | 75.05M |
| December 31, 2024 | 70.02M |
| September 30, 2024 | 65.32M |
| June 30, 2024 | 81.61M |
| March 31, 2024 | 84.47M |
| December 31, 2023 | 90.66M |
| September 30, 2023 | 98.39M |
| June 30, 2023 | 106.24M |
| March 31, 2023 | 109.88M |
| December 31, 2022 | 71.46M |
| September 30, 2022 | 77.18M |
| June 30, 2022 | 86.64M |
| March 31, 2022 | 98.55M |
| December 31, 2021 | 109.30M |
| September 30, 2021 | 117.61M |
| June 30, 2021 | 40.98M |
| March 31, 2021 | 49.70M |
| December 31, 2020 | 31.65M |
| Date | Value |
|---|---|
| September 30, 2020 | 32.16M |
| June 30, 2020 | 36.10M |
| March 31, 2020 | 42.13M |
| December 31, 2019 | 21.19M |
| September 30, 2019 | 26.74M |
| June 30, 2019 | 30.23M |
| March 31, 2019 | 29.48M |
| December 31, 2018 | 33.65M |
| September 30, 2018 | 38.99M |
| June 30, 2018 | 45.38M |
| March 31, 2018 | 54.50M |
| December 31, 2017 | 64.24M |
| September 30, 2017 | 72.29M |
| June 30, 2017 | 40.03M |
| March 31, 2017 | 50.71M |
| December 31, 2016 | 62.80M |
| September 30, 2016 | 73.99M |
| June 30, 2016 | 86.57M |
| March 31, 2016 | 100.43M |
| December 31, 2015 | 115.05M |
| September 30, 2015 | 129.16M |
| June 30, 2015 | 139.34M |
| March 31, 2015 | 43.29M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| MetaVia, Inc. | 6.822M |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 69.82M |
| Total Liabilities (Quarterly) | 21.23M |
| Debt to Equity Ratio | 0.2316 |
| Current Ratio | 5.121 |
| Net Debt Paydown Yield | 0.58% |